Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

elosulfase alfa

VIMIZIM

elosulfase alfa (VIMIZIM) is a chondroitin-6-sulfate hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

FDA: approved EMA: approved Alimentary tract and metabolism (A16) A16AB12
US status approved
Patents linked 20
Pipeline programs 0
News articles 0
Drug details — elosulfase alfa
US status
approved
Class
Alimentary tract and metabolism (A16)
Route
INJECTION
Patents
20
Programs
0
Data quality
0.89
← All drugs Manufacturer profile Related patents Drug news hub Event calendar

Quick answer

elosulfase alfa (VIMIZIM) is a chondroitin-6-sulfate hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN elosulfase alfa
Brand VIMIZIM
Mechanism Chondroitin-6-sulfate hydrolytic enzyme
Target Chondroitin-6-sulfate
Therapeutic class Alimentary tract and metabolism (A16)
Route INJECTION
Formulation INJECTABLE
ATC code A16AB12
Originator BioMarin Pharmaceutical Australia Pty Ltd

Mechanism of action

Chondroitin-6-sulfate hydrolytic enzyme

Primary target: Chondroitin-6-sulfate

Approval history

Authority Status Date
FDA approved —
EMA approved —

Related & competitor drugs

Browse all drugs
  1. agalsidase alfa Alimentary tract and metabolism (A16)
  2. alogliptin Alimentary tract and metabolism (A10)
  3. alogliptin benzoate Alimentary tract and metabolism (A10)
  4. aprepitant Alimentary tract and metabolism (A04)
  5. budesonide Alimentary tract and metabolism (A07)
  6. canagliflozin Alimentary tract and metabolism (A10)

Related patents

Browse patents BioMarin Pharmaceutical Australia Pty Ltd patent hub

  1. US 12427171

    Krill oil composition enriched in LPC-DHA and LPC-EPA

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12214015

    Use of c-type natriuretic peptide variants to treat osteoarthritis

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12194064

    Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12076372

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12076333

    Lysophosphatidylcholine compositions

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12023359

    Phospholipid compositions for delivery of therapeutic compounds

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11918633

    Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11865143

    Bioeffective krill oil compositions

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11819509

    Lipid compositions

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11739345

    Methods of treating phenylketonuria

    Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11505790

    Compositions of prokaryotic phenylalanine ammonia-lyase variants and methods of using compositions thereof

    Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11202819

    Use of C-type natriuretic peptide variants to treat osteoarthritis

    Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11135251

    Methods for improving fillet quality in farmed fish

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11065267

    Lysophosphatidylcholine compositions

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11040088

    Delivery of therapeutic compounds to the brain and other tissues

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11034956

    Oligonucleotide comprising an inosine for treating DMD

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11020438

    Phospholipid compositions and their preparation

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10898525

    Krill oil preparations and their uses

    Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10864223

    Lipid compositions

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10806742

    Liquid phospholipid-containing compositions for the preparation of pharmaceuticals

    Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is elosulfase alfa?

elosulfase alfa (VIMIZIM) is a chondroitin-6-sulfate hydrolytic enzyme. Associated with BioMarin Pharmaceutical Australia Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for elosulfase alfa?

VIMIZIM is a marketed brand name for elosulfase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of elosulfase alfa?

elosulfase alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.